Velocity has won the 2024 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Company at The World Vaccine Congress in Washington, DC. The recognition is based on performance metrics, diversity of vaccine trial capabilities, and key initiatives to support vaccine research. Highlights of our groundbreaking initiatives and achievements throughout the past year include:
- The development of VISION, our AI-enabled technology suite that has already contributed to 1,000+ patient randomizations, primarily in vaccine trials.
- The buildout of in-house laboratory capabilities, including 100% in-network PBMC processing for 30+ locations across the U.S. and Europe.
- The launch of our Vaccine Council to Accelerate Research Excellence (CARE), which provides world-class operational, recruitment, and trial conduct oversight for all Velocity sites conducting infectious disease studies.
- The support of trials that have led to six vaccine approvals in the U.S. in the past two years.
